Hepatocellular Carcinoma Clinical Trial
— HCCOfficial title:
Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)
The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Before doing any research steps, the patient's informed consent must be obtained first. 2. The diagnosis of HCC: histologic diagnosis or Alpha fetoprotein (AFP) with two kinds of imaging diagnosis. 3. Patients of Barcelona stage(BCLC) C with first-line treatment failure or non tolerance to sorafenib. 4. Ages of 18 to 75 years old. 5. Child-Pugh score between 5-7 points, patients of Child-Pugh 7 points should be without ascites. 6. Eastern Cooperative Oncology Group performance score (ECOG PS) is 0-1 point. 7. Adequate organ function meeting the following: Hemoglobin(HBG)?9.0g/dl Neutrophil count(ANC) ?1,500/mm3 Platelet count(PLT)?50,000/ul Total bilirubin (TBIL)< 2mg/dL (3mg/dL, Child-Pugh B) Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 5×ULN (upper limit of normal) ALP (alkaline phosphatase ) < 4×ULN PT (prothrombin time) >50% or PT-INR<2.3, <6 seconds or greater than that of the control 8. For patients taking warfarin, at least once a week to a close monitoring of the patients, until, according to the standard of treatment, at every time of medication, the subjects' INR measurements has been stable 9. SCr (serum creatinine) <1.5×ULN 10. For pregnant women, the results of serum pregnancy tests must be negative within 14 days before initiation of treatment. 11. All men and women who participated in the study had to take reliable contraceptive measures within the trial and two weeks of after the trial. Exclusion Criteria: 1. Patients of Child-Pugh 7 has serious uncontrolled ascites. 2. Patients with serious cardiovascular disease. 3. Patients with high blood pressure of unable to control. 4. Patients has the history of HIV (human immunodeficiency virus) infection. 5. Active clinical severe infection (> 2, NCI-CTCAE version 3). 6. Need to drug treatment of patients with epilepsy (such as steroid or antiepileptic drugs) 7. Has a history of allogeneic organ transplantation. 8. Patients with a history of physical signs or have a bleeding. 9. Patients undergoing renal dialysis. 10. Metastatic liver cancer. 11. Patients with uncontrollable ascites. 12. Patients with encephalopathy. 13. Patients has history of gastrointestinal bleeding period of 30 days before join the study. 14. Patients with a history of esophagus varicosity burst hemorrhage, then not effective treatment or therapy to prevent recurrence of bleeding. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate(ORR) | one year | ||
Secondary | Disease Control Rate (DCR) | one year | ||
Secondary | Progression free survival (PFS) | one year | ||
Secondary | Overall survival (OS) | one year | ||
Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0[Quality of life] | one year | ||
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety] | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |